AMR: IMI’s Enable project reaches endpoints

  29 January 2020

The IMI project was recently granted a one-year extension to promote further progression of ongoing programmes, while keeping within the original budget of about €100m. ENABLE was formed in 2014 to accelerate the development of new antibiotics for the treatment of difficult-to-treat Gram-negative  infections. The project has so far identified five antibacterial leads.

Further reading: European Biotechnology
Author(s): TG
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





EADA 2023

Emerging Antimicrobials and Diagnostics in AMR 2023

International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands
16/17 November

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!